Yiwei Sun, Rui Ni, Yuan-Yuan Liu, Haifang Wang, Aoneng Cao
{"title":"多特异性抗gp120人工抗体的研制","authors":"Yiwei Sun, Rui Ni, Yuan-Yuan Liu, Haifang Wang, Aoneng Cao","doi":"10.1002/cmdc.202500287","DOIUrl":null,"url":null,"abstract":"<p><p>Broadly neutralizing antibodies are potential therapeutic drugs that can recognize and block viral entry. But many viruses, such as human immunodeficiency virus (HIV), mutate rapidly and thus evade therapeutic antibodies. Multispecific antibodies and combinations of different antibodies can effectively suppress immune evasion. However, many barriers hinder the development of multispecific antibodies, and the cost of combining multiple antibodies is very high. Previously, a class of gold nanoparticle (AuNP)-based artificial antibodies, called goldbodies, were created by simply grafting the complementary-determining regions of antibodies onto AuNPs. In this study, four monospecific anti-gp120 goldbodies are created by grafting the HIV gp120-binding fragment of the CD4 protein and the CDR3 loops of three anti-gp120 antibodies onto AuNPs, respectively. Remarkably, as a first proof of concept, the study shows that all four different fragments can be grafted onto the same AuNP particle, thus creating a new type of goldbody with a very high binding affinity for gp120. In principle, this new type of goldbody costs the same as a single monospecific goldbody, but it has the potential to serve as a multispecific goldbody or a combination of multiple goldbodies.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e2500287"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Towards Multispecific Anti-Gp120 Artificial Antibody.\",\"authors\":\"Yiwei Sun, Rui Ni, Yuan-Yuan Liu, Haifang Wang, Aoneng Cao\",\"doi\":\"10.1002/cmdc.202500287\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Broadly neutralizing antibodies are potential therapeutic drugs that can recognize and block viral entry. But many viruses, such as human immunodeficiency virus (HIV), mutate rapidly and thus evade therapeutic antibodies. Multispecific antibodies and combinations of different antibodies can effectively suppress immune evasion. However, many barriers hinder the development of multispecific antibodies, and the cost of combining multiple antibodies is very high. Previously, a class of gold nanoparticle (AuNP)-based artificial antibodies, called goldbodies, were created by simply grafting the complementary-determining regions of antibodies onto AuNPs. In this study, four monospecific anti-gp120 goldbodies are created by grafting the HIV gp120-binding fragment of the CD4 protein and the CDR3 loops of three anti-gp120 antibodies onto AuNPs, respectively. Remarkably, as a first proof of concept, the study shows that all four different fragments can be grafted onto the same AuNP particle, thus creating a new type of goldbody with a very high binding affinity for gp120. In principle, this new type of goldbody costs the same as a single monospecific goldbody, but it has the potential to serve as a multispecific goldbody or a combination of multiple goldbodies.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\" \",\"pages\":\"e2500287\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cmdc.202500287\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Towards Multispecific Anti-Gp120 Artificial Antibody.
Broadly neutralizing antibodies are potential therapeutic drugs that can recognize and block viral entry. But many viruses, such as human immunodeficiency virus (HIV), mutate rapidly and thus evade therapeutic antibodies. Multispecific antibodies and combinations of different antibodies can effectively suppress immune evasion. However, many barriers hinder the development of multispecific antibodies, and the cost of combining multiple antibodies is very high. Previously, a class of gold nanoparticle (AuNP)-based artificial antibodies, called goldbodies, were created by simply grafting the complementary-determining regions of antibodies onto AuNPs. In this study, four monospecific anti-gp120 goldbodies are created by grafting the HIV gp120-binding fragment of the CD4 protein and the CDR3 loops of three anti-gp120 antibodies onto AuNPs, respectively. Remarkably, as a first proof of concept, the study shows that all four different fragments can be grafted onto the same AuNP particle, thus creating a new type of goldbody with a very high binding affinity for gp120. In principle, this new type of goldbody costs the same as a single monospecific goldbody, but it has the potential to serve as a multispecific goldbody or a combination of multiple goldbodies.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.